• Apigenin: Limits of Preclinical Evidence

  2026-10-13

  Apigenin, or 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one, is being investigated in cancer and neurodegeneration models. A 2025 network-medicine study reported neuroprotective effects in cellular Alzheimer’s disease models, while supplier summaries describe separate malignant mesothelioma findings. Together, these results support mechanistic interest, not clinical efficacy.

• What Dual Tracing Shows About Mouse Neo-Oogenesis

  2026-10-13

  A pre-proof study provides convergent lineage-tracing evidence against detectable postnatal neo-oogenesis in mice under the tested physiological and injury conditions, while leaving important questions about labeling sensitivity, rare events, injury models, and relevance to humans.

• What Aβ42 Fluorescent Probes Can—and Cannot—Show

  2026-10-12

  A 2024 Inorganic Chemistry study reports a ratiometric ruthenium probe for distinguishing amyloid-β aggregation signals, including Aβ42 fibrils. The findings support an in-vitro sensing principle, but they do not establish Alzheimer’s disease causation, clinical diagnostic performance, or therapeutic value.

• Mavorixafor and CXCR4: Evidence Boundaries

  2026-10-12

  A source-grounded overview of AMD-070 hydrochloride, the CXCR4 signaling rationale in WHIM syndrome, reported phase 3 findings, and the limits of applying those findings to other diseases or research contexts.

• 3D Collagen Microtissues for Cancer Drug Research

  2026-10-10

  A 2026 study developed free-floating collagen microtissues through modular tissue engineering to model hypoxia, stemness-related phenotypes, and treatment resistance in triple-negative breast cancer. Its findings suggest that this relatively accessible 3D platform can complement conventional monolayers and other 3D systems, while remaining limited by its cancer-cell-only design and in vitro scope.

• Mestranol and Reversible Lysosomal Stress in Microglia

  2026-10-09

  A 2026 Aquatic Toxicology study identifies mestranol as an inducer of a reversible lysosomal storage–like state in zebrafish microglia. The work separates impaired intracellular digestion from loss of phagocytic capacity or neuronal apoptosis, providing a live model for studying estrogen-associated neuroimmunotoxicity.

• CHK1 Inhibition in Receptor-Stratified Breast Cancer

  2026-10-09

  Xu and colleagues showed that CHK1 inhibition has different therapeutic implications across breast cancer models defined by ER, PR, and HER2 status. The study’s central innovation was to connect receptor context with distinct mechanisms of chemotherapy sensitization and single-agent activity, supporting biomarker-informed interpretation of CHK1-targeted strategies.

• WRN–MSI Synthetic Lethality in Colorectal Cancer

  2026-10-08

  The reference study identifies a p53/PUMA-mediated apoptotic mechanism underlying the selective vulnerability of mismatch repair-deficient, microsatellite-instability colorectal cancers to Werner helicase loss. Its genetic, pharmacological, and xenograft evidence supports WRN as a context-dependent therapeutic target, particularly in p53-wildtype MSI tumors, while also highlighting the need to distinguish WRN biology from broader RecQ helicase inhibition.

• Mestranol and Reversible Lysosomal Stress in Microglia

  2026-10-08

  A 2026 Aquatic Toxicology study identifies mestranol as an inducer of a reversible lysosomal storage–like state in zebrafish microglia. The findings separate preserved phagocytic uptake from impaired intracellular digestion and provide a live model for studying environmental estrogen-associated neuroimmunotoxicity.

• Gingerenone A, LDHA, and Sunitinib Resistance

  2026-10-07

  A January 2026 study reports that gingerenone A suppresses LDHA-associated glycolysis and improves sunitinib response in renal cell carcinoma models. Its central contribution is a preclinical mechanistic link between metabolic intervention, HIF-1α–angiogenic signaling, and reversal of treatment resistance, although clinical relevance remains to be established.

• RWJ 67657 and the Next p38 Strategy

  2026-10-07

  RWJ 67657, also known as JNJ-3026582, offers a useful lens for connecting selective p38α/β inhibition with activation-loop dephosphorylation. This thought-leadership analysis separates established findings from translational hypotheses and outlines how researchers can evaluate its relevance to inflammatory disease research.

• Novel Allosteric PDK4 Inhibitors: Study Insights

  2026-10-06

  Lee and colleagues identified a new anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors, with compound 8c showing 84 nM in vitro activity and evidence of metabolic, allergic, and cancer-related effects. The study supports PDK4 as a tractable metabolic target while leaving important questions about selectivity, mechanism, pharmacology, and clinical translation.

• Doxorubicin Beyond the Product Page

  2026-10-06

  Doxorubicin, also known as Adriamycin, remains a powerful translational reference compound because it links DNA damage, chromatin disruption, apoptosis, and therapeutic trade-offs. This thought-leadership analysis places its mechanism alongside historical small-cell lung cancer evidence, outlines validation priorities, and defines how researchers can extract stronger biological insight without overextending preclinical findings.

• IL-7 and ER Proteostasis in SARS-CoV-2 Research

  2026-10-05

  A translational perspective on how SARS-CoV-2 PLpro reshapes ER protein control—and why IL-7 research should be interpreted within a broader immune-state framework.

• Sulfo-Cy3 azide and Claustrum Development

  2026-10-05

  Explore how the Sulfo-Cy3 azide bioconjugation reagent can be interpreted within a rigorous framework for developmental neuroscience. This evidence-led article separates fluorescent signal quality from claims about Nurr1-positive neuron birth timing, identity, and spatial organization.

8177 records 1/546 page Next 12345 下5页 Last page